Monday 25 July 2016

Syngene surges 1%; plans US$ 200 mn for capex

The company plans to invest $100 million (around Rs.665 crore) in a greenfield facility at Mangalore, the first phase of which would be operationalised by financial year 2018-19.

Biocon
Biocon’s research arm Syngene International is currently trading 1% higher at Rs.430 on BSE. The company has lined up US$ 200 million for capital expenditure.

The company plans to invest $100 million (around Rs.665 crore) in a greenfield facility at Mangalore, the first phase of which would be operationalised by financial year 2018-19. Besides, it has also earmarked another $100 million to create additional infrastructure at its existing facility at Bangalore.

Syngene International Ltd is currently trading at Rs. 429.1, up by Rs. 3.95 or 0.93% from its previous closing of Rs. 425.15 on the BSE.

The scrip opened at Rs. 426.9 and has touched a high and low of Rs. 434.8 and Rs. 426 respectively. So far 70092(NSE+BSE) shares were traded on the counter. The current market cap of the company is Rs. 8503 crore.

The BSE group 'B' stock of face value Rs. 10 has touched a 52 week high of Rs. 458 on 05-Jul-2016 and a 52 week low of Rs. 295 on 11-Aug-2015. Last one week high and low of the scrip stood at Rs. 438 and Rs. 408 respectively.

The promoters holding in the company stood at 74.55 % while Institutions and Non-Institutions held 15.71 % and 6.85 % respectively.

The stock is currently trading above its 50 DMA.

No comments:

Post a Comment